Shares of Repligen have moved 2.0% today, and are now trading at a price of $170.48. In contrast, the S&P 500 index saw a -1.0% change. Today's trading volume is 1,177,969 compared to the stock's average volume of 605,530.
Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. Based in Waltham, United States the company has 2,025 full time employees and a market cap of $9,492,326,400.
The company is now trading -13.06% away from its average analyst target price of $196.08 per share. The 12 analysts following the stock have set target prices ranging from $157.0 to $250.0, and on average give Repligen a rating of buy.
Over the last 12 months RGEN shares have declined by -29.0%, which represents a difference of -39.0% when compared to the S&P 500. The stock's 52 week high is $262.26 per share and its 52 week low is $134.64. Based on Repligen's average net margin growth of 30.8% over the last 4 years, its core business remains strong and the stock price may recover in the long term.
| Date Reported | Total Revenue ($ k) | Net Profit ($ k) | Net Margins (%) | YoY Growth (%) |
|---|---|---|---|---|
| 2023-02-22 | 801,536 | 185,959 | 23.2 | 21.28 |
| 2022-02-17 | 670,534 | 128,291 | 19.13 | 16.93 |
| 2021-02-24 | 366,260 | 59,926 | 16.36 | 106.57 |
| 2020-02-26 | 270,245 | 21,411 | 7.92 | n/a |
